The Heart, Vessel, Blood CTSU is supporting two interventional studies sponsored by MyoKardia in Phase 2 and Phase 3 development. The drug Mavacamten, is being studied in adults with Symptomatic Non-Obstructive (nHCM) and Obstructive (oHCM) Hypertrophic Cardiomyopathy.
Hypertrophic Cardiomyopathy (HCM) is one of the most common genetic cardiac conditions with over 650,000 cases per year in the U.S. HCM is a disease where the heart muscle becomes abnormally thick, making it difficult for the heart to pump blood. HCM can affect people of any age and occurs in men and women equally.
The Phase 2 study, MAVERICK, led by Principal Investigator, Sharlene Day, MD, is a multicenter, exploratory, randomized, double-blind study of the administration of Mavacamten in 60 participants with symptomatic nHCM. The Phase 3 study, EXPLORER, led by Principal Investigator, Sara Saberi, MD, is a multicenter, international, double-blind study of the administration of Mavacamten in 220 participants with symptomatic oHCM and is actively recruiting.
"We are happy to be partnering with MyoKardia to run these studies at Michigan Medicine," said Ann Cornicelli, Lead Administrator, HVB CTSU. "Mavacamten has made great strides in treating this often undetectable genetic disease."
In earlier studies, Mavacamten has shown to reduce ventricular filling pressures, improve symptoms, and increase exercise capacity.
Learn more about Phase 2 MAVERICK and Phase 3 EXPORER studies.